Day: May 14, 2021

AUSTIN, May 14, 2021 (GLOBE NEWSWIRE) — AYRO, Inc. (Nasdaq: AYRO) a designer and manufacturer of light-duty, short-haul, and last-mile delivery electric vehicles (EVs), today announced that management will participate at the Investor Summit Conference on May 17, 2021. Chief Executive Officer Rod Keller will deliver his corporate presentation at 3:30pm ET on May 17, 2021. Investors can also request a one-on-one meeting with Mr. Keller to be arranged following the conclusion of the conference. Investors can register for the conference here. About AYRO, Inc. Texas-based AYRO, Inc., engineers and manufactures purpose-built electric vehicles to enable sustainable fleets. With rapid, customizable deployments that meet specific buyer needs, AYRO’s agile EVs are an eco-friendly microdistribution alternative to gasoline vehicles. The AYRO...

InfographicNet revenue breakdown among business lines in the commercial cycle to date, 2021 vs. 2020 (R$ million)SÃO PAULO, Brazil, May 14, 2021 (GLOBE NEWSWIRE) — Vasta Platform Limited (NASDAQ: VSTA) – “Vasta” or the “Company,” announces today its financial and operating results for the first quarter of 2021 (4Q21) ended March 31, 2021. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). HIGHLIGHTSRevenue from subscription products ex-PAR jumped 20% in the 4Q20 and 1Q21 combined (2021 commercial year to date), in comparison to the same period of last year. This increase is slightly below the 23% growth in ACV, owing to the lower number of students at partner schools due to the Covid-19 effects. The PAR learning system,...

LAS VEGAS, NV, May 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — ISW Holdings, Inc. (OTC: ISWH) (“ISW Holdings” or the “Company”), a global brand management holdings company with commercial operations in Telehealth and Cryptocurrency Mining, is pleased to announce that the Company’s Board of Directors has officially approved a significant share buyback program for immediate activation. The size of the Buyback program has been initially set at up to $250k, but may be expanded in the future. “We have substantial cash reserves, strong growth expectations, and expanding productive resources targeting rapidly growing end markets, as well as an absolute commitment to delivering shareholder value over the long term,” stated Alonzo Pierce, President and Chairman of ISW Holdings. Management notes the Company has strengthened its...

Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on target to report in calendar Q3 2021Recently reported topline data from the NORSE THREE open-label safety study reinforce positive safety profile of ONS-5010 seen in the earlier clinical experience trial (NORSE ONE)ISELIN, N.J., May 14, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2021. Outlook Therapeutics also provided a clinical development and pre-commercialization update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic formulation of...

16th Annual Needham Virtual Technology & Media Conference, May 20, 2021 Stifel Cross Sector Insight Conference, June 9, 2021 JERSEY CITY, N.J., May 14, 2021 (GLOBE NEWSWIRE) — Bel Fuse Inc. (“Bel,” or, “the Company”) (Nasdaq:BELFA and Nasdaq:BELFB), a leading supplier of products that power, protect and connect electronic circuits, today announced that management will participate in two upcoming investor conferences that are being held virtually, the 16th Annual Needham Virtual Technology & Media Conference and the Stifel Cross Sector Insight Conference. Senior management from Bel will be available to meet virtually with investors in one-on-one sessions at each of these conferences, and interested parties may schedule a one-on-one meeting in advance of the conference through the respective hosts’ on-line meeting platforms,...

SHELTON, Conn., May 14, 2021 (GLOBE NEWSWIRE) — Acme United Corporation (NYSE American: ACU) will present at the Sidoti Microcap Virtual Conference on Wednesday, May 19, 2021 at 11:30am EDT. Acme United’s Chairman and Chief Executive Officer Walter Johnsen will also meet one-on-one with institutional investors on Wednesday, May 19th. A webcast of Acme United’s presentation and supporting material will be available in the Investor Relations section of the company’s website at: https://acmeunited.gcs-web.com/. To obtain additional information about Acme United’s participation in the Sidoti Spring 2021 Virtual Conference please contact Sidoti & Company. About Acme United ACME UNITED CORPORATION is a leading worldwide supplier of innovative safety solutions and cutting technology to the school, home, office, hardware, sporting...

WALL, N.J., May 14, 2021 (GLOBE NEWSWIRE) — BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of biometric and multi-factor identity and access management (IAM) solutions for strong, convenient user authentication and large-scale identity applications, today reported results for its first quarter ended March 31, 2021 (Q1’21). BIO-key will host a conference call today at 10:00 a.m. ET (details below) to review its results and outlook. Q1 & Recent Highlights:BIO-key began initial technology deployments for its large-scale ID projects in Africa, recording hardware revenue of $680k in Q1. BIO-key secured a $1.2M, three-year contract extension from a Fortune 500 telecommunications customer for fingerprint biometric security support services.   BIO-key added new higher education customer contracts in the quarter,...

JOHNS CREEK, Ga., May 14, 2021 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries today announced that the Company will report its 2021 first quarter results on Monday, May 17th, 2021, and will host an investor conference call at 11:00 am ET on the same day to discuss the Company’s performance. The call is open to the public.Conference Call, Webcast and Replay Details:Call Date/Time:   May 17, 2021 at 11:00 a.m. ETCall Dial-In Toll Free:   +1 (877) 837-3909International Dial-In:   +1 (973) 409-9690Call ID:   # 9598823     Live Audio Webcast:   https://www.ebix.com/webcast     Audio Replay URL:   http://www.ebix.com/result_21_q1 after 2:00 p.m.About EbixWith...

– Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at American Society of Gene & Cell Therapy Annual Meeting, Enabling Anticipated Clinical Trials This Year PALO ALTO, Calif., May 14, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BBP-631, an investigational adeno-associated virus 5 (AAV5) gene therapy designed for the treatment of congenital adrenal hyperplasia (CAH). Fast Track designation, granted by the FDA, is designed to facilitate the development and to expedite the review of...

OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. OTO-825 is an AAV-mediated gene therapy targeting the gap junction beta-2 (GJB2) gene developed under the company’s collaboration with Applied Genetic Technologies Corporation (Nasdaq: AGTC). These results demonstrate that a single administration of OTO-825 rescues hearing loss and cochlear damage in two preclinical models that represent a range of hearing loss severity caused...